Background: Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed this study with new effective drug combination.

A thin, highly crosslinked layer was grafted onto an alkyl thiol self‐assembled‐monolayer (SAM)‐coated gold surface with N,N′‐methylene bisacrylamide (MBAA), a widely used crosslinker with two polymerizable groups, as the monomer. Surface‐initiated photografting copolymerization was achieved through the immobilization of the hydrogen‐abstraction photoinitiator benzophenone on the hydrophobic alkyl surface via physical adsorption and subsequent UV irradiation in the presence of an MBAA solution. The growth of the grafted poly‐MBAA layers seemed to produce dendritic structures with low surface coverage. At a higher monomer concentration (15 g/L of water), full coverage of the gold surface with a thin layer was obtained and proved by scanning force microscopy and contact‐angle measurements. The evaluation of the gold, gold–SAM, and gold–SAM/grafted poly‐MBAA layers with a surface plasmon resonance sensor system revealed that the photografted, thin, highly crosslinked polyacrylamide layers had a very low affinity toward the adsorption of protein. Therefore, this provides a very promising approach to tailoring materials for sensors and other applications. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci 97: 158–164, 2005

Composite pheochromocytoma-ganglioneuroma is one of the mixed neuroendocrine-neural tumors composed of pheochromocytoma and other neural crest derivatives. To date, less than 50 cases of composite pheochromocytoma have been reported, and about 70% of the accompanying tumors were ganglioneuromas. Here, we describe six cases of composite pheochromocytoma-ganglioneuromas in five men and one woman, aged 33 to 64. The size of the tumors ranged from 3.0 to 11.0 cm, and four out of the six presented with intermittent onset of hypertension, palpitation, or dizziness. Microscopically, each tumor was composed of large pleomorphic shaped chromaffin cells arranged in the Zellballen patterns characteristic of pheochromocytoma, and they were mixed with clusters of mature ganglion cells and bundles of spindle-shaped Schwann cells characteristic of ganglioneuroma of variable proportions. All were successfully treated laparoscopically, and none were associated with multiple endocrine neoplasm syndrome or neurofibromatosis. Preoperative diagnosis of a composite pheochromocytoma-ganglioneuroma is impossible because of the low incidence rate, and the radiological findings and symptoms are similar to those of typical pheochromocytomas. Although the significance of microscopic detection of the nonpheochromocytoma component from pheochromocytoma has not yet been clarified, microscopic identification of the composite pheochromocytoma-ganglioneuroma is important because cumulative cases are used in an effort to predict the behavior of this composite tumor. (Endocrinol Metab 26:340-344, 2011)

No abstract

BackgroundThalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC). We evaluated the safety and efficacy of using thalidomide for treating selected patients with unresectable or metastatic HCC, and their disease was refractory to systemic chemotherapy.MethodsEight patients with measurable and metastatic HCC that had progressed with prior systemic chemotherapy and who desired further active therapy were enrolled in this study. Thalidomide was given orally at bedtime and it was started at 200 mg/day with no further dose escalation. The response was measured at 2-month intervals.ResultsThe median age was 44 years (range: 34-52 years) and all the patients had received doxorubicin-based systemic chemotherapy prior to their enrollment. Each patient received thalidomide for a median of 152 days (range: 5-422 days). One partial response was observed (12.5%, 95% CI; 0-42%) along with 4 cases of stable diseases. The most commonly encountered toxicity was somnolence; grade 3 somnolence was noted for one patient, which led to treatment discontinuation. Skin rash was observed in one responding patient.ConclusionsThe results indicate that thalidomide may feasibly offer disease stabilization to metastatic HCC patients. Further dose escalation of thalidomide, or its combination with other chemotherapeutic agents, may be of interest and this should be investigated for treating patients with metastatic HCC.